|
See related Velcade powd for inj information |
|
|
|
Manufacturer |
Janssen-Cilag |
|
Distributor |
DKSH |
|
Contents |
Bortezomib |
|
Indications |
Combination therapy for treatment of previously untreated multiple myeloma. Treatment of mantle cell lymphoma (w/ at least 1 prior therapy).
Click to view Velcade detailed prescribing infomation |
|
Dosage |
Adult 1.3 mg/m2/dose as a bolus IV inj twice wkly for 2 wk (days 1, 4, 8 & 11) followed by a 10-day rest period (days 12-21). Treatment Cycle: 3 wk. At least 72 hr should elapse between consecutive doses. Responding patients may receive up to 8 cycles of therapy. Combination therapy 3-5 second bolus IV inj in combination w/ oral melphalan & prednisone for nine 6-wk treatment cycles. Twice wkly in cycles 1-4 (days 1, 4, 8, 11, 22, 25, 29, 32), & once wkly in cycles 5-9 (days 1, 8, 22, 29).
Click to view Velcade detailed prescribing infomation |
|
Overdosage |
View Velcade overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
[Click for Velcade detailed prescribing infomation] |
|
Special Precautions |
Peripheral neuropathy may develop or worsen; monitor patients for symptoms. History of syncope; patients taking drugs associated w/ hypotension; dehydrated patients. CHF may develop or exacerbate; monitor patients w/ risk factors for or existing heart disease. Monitor CBC, platelet counts. Patients at risk of tumor lysis syndrome. Hepatic impairment. CrCl <13 mL/min & patients on hemodialysis. Pregnancy & lactation.
Click to view Velcade detailed prescribing infomation |
|
Adverse Drug Reactions |
Fatigue, malaise & weakness, nausea, diarrhea, decreased appetite (including anorexia), constipation, thrombocytopenia, peripheral neuropathy (including peripheral sensory neuropathy & aggravated peripheral neuropathy), pyrexia, vomiting, anemia, neutropenia.
View ADR Monitoring Form |
|
Drug Interactions |
Cytochrome P-450 3A4 inhibitors or inducers. Oral antidiabetic agents. Drugs associated w/ peripheral neuropathy (eg amiodarone, antivirals, INH, nitrofurantoin or statins) or w/ a decrease in BP.
View more drug interactions with Velcade |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Velcade detailed prescribing infomation |
|
Storage |
View Velcade storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Velcade description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Velcade mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Velcade powder for injection |
|
Velcade 1 mg x 5 mL x 1's |
|
Velcade 3.5 mg x 10 mL x 1's |
 |
|
|
|
Manufacturer: |
Janssen-Cilag |
|
Distributor: |
DKSH |
|
 |
|
|
|
